You are here: Industry Insights > DLBCL

News List

Antengene Submits New Drug Application for Selinexor in Taiwan, China for the Treatment of Three Indications in Hematologic Malignancies prnasia
July 14, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has ...
ADC Therapeutics gets USFDA nod for ZYNLONTA to treat relapsed or refractory diffuse large B-cell lymphoma expresspharma
April 26, 2021
First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL prnasia
April 13, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, presented preclinical data at ...
CAR T therapy provides long-lasting remissions in non-hodgkin lymphoma europeanpharmaceuticalreview
February 20, 2021
Study shows most non-Hodgkin’s lymphoma patients who achieve a remission lasting one year remain in remission for five years after receiving Novartis’ Kymriah™.
FDA approves third gene therapy for large B-cell lymphoma europeanpharmaceuticalreview
February 09, 2021
Breyanzi (lisocabtagene maraleucel) was approved on the 54 percent complete remission rate achieved in diffuse large B-cell lymphoma trials.
ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma pharmaceutical-business-review
November 24, 2020
ADC Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for loncastuximab tesirine (Lonca) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and ...
FDA Grants Accelerated Approval to tafasitamab-cxix for Diffuse Large B-Cell Lymphoma americanpharmaceuticalreview
August 12, 2020
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tafasitamab-cxix (MONJUVI, MorphoSys US).
ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo pharmaceutical-business-review
July 22, 2020
ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed ...
FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma americanpharmaceuticalreview
July 03, 2020
The Food and Drug Administration (FDA) granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ...
PET Helps Tailor Therapy in Limited-Stage DLBCL drugs
December 25, 2019
Positron emission tomography (PET)-directed therapy results in excellent outcomes for patients with stage I/II diffuse large B-cell lymphoma (DLBCL) ...

Previous page 1 2 Next page